lipo.gif Back grey_arrow_rt.gif
 
People living with HIV face numerous challenges when managing their health. One of the distressing observations includes visible changes in body shape and appearance. Although some aspects of this phenomenon were seen in earlier years of the epidemic, reports have increased since 1996 with the widespread use of three-drug anti-HIV therapy.
 
Although there is no precise, agreed upon definition of the term, these changes of fat redistribution in the body and related irregularities in certain blood tests are typically called lipodystrophy. Only some people with HIV on anti-HIV therapy develop lipodystrophy and its true prevalence is unknown.
 
null.gif
 
 
  1. Webcasts from the 10th Intl Workshop on Adverse Drug Reactions & Lipodystrophy
     
  2. Myocardial Dysfunction With Contemporary Management of HIV Prevalence, Pathophysiology, and Opportunities for Prevention / Belly Fat-VAT-Lipodystrophy - (01/29/19)
     
  3. Tesamorelin & IGF-1 Levels - (05/28/10)
     
  4. Tesamorelin Reduces VAT: FDA Hearing - (05/28/10)
     
  5. VOTE: 16-0 to recommend approval for tesamorelin - 'benefit outweighs risk' - (05/28/10)
     
  6. 10th Intl Workshp Adverse Drug Reactions & Lipo: Report from the 10th Intl Workshop on Adverse Drug Reactions and Lipodystrophy in HIV - written by Michael Dube, MD - (12/13/08)
     
  7. 10th Intl Workshp Adverse Drug Reactions & Lipo: A Comparison of Cardiac Function Between HIV-Infected and HIV-Seronegative People With and Without the Metabolic Syndrome. - (12/10/08)
     
  8. 10th Intl Workshp Adverse Drug Reactions & Lipo: COMPARISON OF THE EFFECTS OF NEVIRAPINE RESPECT TO EFAVIRENZ ON DIFFERENTIATING AND MATURE HUMAN ADIPOCYTES IN CULTURE - (12/10/08)
     
  9. ICAAC: Continuous Antiretroviral Therapy Decreases Bone Mineral Density: Results from the SMART Study (11/24/08)
     
  10. ICAAC: Bone Loss in SMART Study - Written by Mark Mascolini - (10/30/08)
     
  11. 10th Intl Workshp Adverse Drug Reactions & Lipo: Effect of HAART on insulin sensitivity, autonomic nervous system function and beta-adrenergic mediated lipolysis (11/20/08)
     
  12. 10th Intl Workshp Adverse Drug Reactions & Lipo: Efavirenz induces alterations in lipid metabolism through AMPK activation (11/20/08)
     
  13. 10th Intl Workshp Adverse Drug Reactions & Lipo: COMPARISON OF THE EFFECTS OF LOPINAVIR/RITONAVIR AND EFAVIRENZ ON GENE EXPRESSION AND DIFFERENTIATION OF HUMAN ADIPOCYTES (11/20/08)
     
  14. 10th Intl Wrkshp Drug Reactions & Lipo: Impact of body changes on the quality of life of HIV-positive treatment experienced patients An online community-based survey (11/10/08)
     
  15. 10th Intl Wrkshp Drug Reactions & Lipo: Skeletal muscle mitochondrial proteins discordantly regulated by insulin in HIV+ with insulin resistance: a mass spectrometry-based muscle proteomics study (11/10/08)
     
  16. 10th Intl Wrkshp Drug Reactions & Lipo: Association between Peripheral Lipoatrophy and Bone Demineralisation in Treated HIV-positive Males (11/10/08)
     
  17. 10th Intl Wrkshp Drug Reactions & Lipo: Effect of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor (GRF) Analogue, on Visceral Adipose Tissue (VAT) in HIV-Infected Patients with Excess Abdominal Fat: Impact of Antiretroviral Therapy Regimen (11/10/08)
     
  18. 10th Intl Wrkshp Drug Reactions & Lipo: CD4 and Undetectable Viral Load Predict Non-AIDS Cancers: "AIDS and non-AIDS defining malignancies in HIV-infected patients - The 2006 ONCOVIH French study" (11/10/08)
     
  19. 10th Intl Wrkshp Drug Reactions & Lipo: Comparison of Directly Measured and Estimated Glomerular Filtration Rates in Virologically Suppressed Patients Switching to Tenofovir or Continuing Zidovudine (11/10/08)
     
  20. CROI: Influence of NRTI Choice and Efavirenz Versus Lopinavir Treatment Options on Lipoatrophy-Associated Adipose Tissue Toxicity: A Longitudinal Study - (03/07/08)
     
  21. Hemochromatosis Gene Polymorphisms, Mitochondrial Haplogroups, and Peripheral Lipoatrophy during ART - (03/05/08)
     
  22. CROI: Lipoatrophy and lipohypertrophy are independently associated with hypertension (FRAM): the effect of lipoatrophy but not lipohypertrophy on hypertension is independent of obesity - (03/07/08)
     
  23. HIV-Associated Lipoatrophy: Letting the Genome Out of the Bottle (Genetic Predisposition & Chronic Inflammation) EDITORIAL COMMENTARY - (03/05/08)
     
  24. Endothelial Activation Markers Are Linked to HIV Status and Are Independent of ART and Lipoatrophy - (03/05/08)
     
  25. HIV-Associated Lipoatrophy: Letting the Genome Out of the Bottle (Genetic Predisposition & Chronic Inflammation) EDITORIAL COMMENTARY - (03/05/08)
     
  26. CROI: Do Lipid Signals Favor Maraviroc Over Efavirenz in Untreated People? - Written by Mark - (02/26/08)
     
  27. 9th Intl Wrkshp on Adverse Drug Reactions and Lipo: Dyslipidemia & Body Changes in Vertically Infected Children & Youth on PI ART: preliminary results of PACTG 1045 - (08/21/07)
     
  28. Treatment for lipoatrophy: facing the real costs; should be reimbursed EDITORIAL COMMENT - (08/15/07)
     
  29. 9th Intl Wrkshp on Adverse Drug Reactions and Lipo: Does diabetes mellitus (DM) confer an equivalent risk of coronary heart disease (CHD) to pre-existing CHD in HIV-positive individuals? - (08/13/07)
     
  30. 9th Intl Wrkshp on Adverse Drug Reactions and Lipo: Lack of Association between Antiretroviral Therapy and Predictors of Endothelial Function and Cardiovascular Disease (CVD) Risk Among HIV-Infected Persons on Long-Term HAART pioglitazone increased limb fat, exercise reduced limb fat - (08/13/07)
     
  31. 9th Intl Wrkshp Adverse Drug & Lipo: Pioglitazone ± exercise training reduces liver lipid content and improves insulin sensitivity in HIV with impaired glucose tolerance; pioglitazone increased limb fat, exercise reduced limb fat - (08/09/07)
     
  32. 9th Intl Wrkshp Adverse Drug & Lipo: Effects of tipranavir/r in comparison with lopinavir/r on changes in body composition and metabolic parameters in ARV-naive patients over 48 weeks - (08/06/07)
     
  33. 9th Intl Wrkshp Adverse Drug & Lipo: Effects of alternate treatment protocols (discontinuation vs viral suppression) on the incidence of electrocardiographic abnormalities among HIV-infected adults in the SMART trial - (08/06/07)
     
  34. 9th Intl Wrkshp Adverse Drug & Lipo: Racial Differences in Long-Term Changes in Metabolic and Body Composition Parameters in Antiretroviral Naive Persons Initiating HAART: Results of the CPCRA 061 Metabolic Study - (08/06/07)
     
  35. 9th Intl Wrkshp Adverse Drug & Lipo: Zidovudine/lamivudine persistently contributes to peripheral insulin resistance by a body composition-independent mechanism demonstrated by repeated clamp studies during 2 years of first line ART with zidovudine/lamivudine/lopinavir/r - (08/06/07)
     
  36. 9th Intl Wrkshp Adverse Drug & Lipo: Effects of 4 weeks of atazanavir, lopinavir/ritonavir, or placebo on endothelial function and insulin sensitivity in healthy men - (07/20/07)
     
  37. 9th Intl Wrkshp Adverse Drug & Lipo: Relationship of body composition, antiretroviral use, and HIV disease factors to endothelial dysfunction in HIV-infected subjects: lipoatrophy associated with endothelial dysfunction - (07/20/07)
     
  38. 9th Intl Wrkshp Adverse Drug & Lipo: Lack of evidence of Metabolic Abnormalities and Mitochondrial Toxicity with Enfuvertide: a double-blind, placebo-controlled, cross-over study with random sequence assignation in healthy adult volunteers - (07/20/07)
     
  39. 9th Intl Wrkshp Adverse Drug & Lipo: HIV, ART & Endothelial Dysfunction - (07/20/07)
     
  40. 9th Intl Wrkshp Adverse Drug & Lipo: Nevirapine Increases High Density Lipoprotein-Cholesterol (HDL-C) by Stimulation of Apolipoprotein AI Synthesis - (07/19/07)
     
  41. 9th Intl Wrkshp Adverse Drug & Lipo: Nevirapine Hypersensitivity is Different for Treatment-Experienced - (07/19/07)
     
  42. 9th Intl Wrkshp Adverse Drug & Lipo: TH9507, Growth Hormone Releasing Factor - (07/19/07)
     
  43. rHGH Reduced Belly Fat; Safety Concerns: glucose, limb fat - (06/28/07)
     
  44. Metabolic Issues Associated With Protease Inhibitors - (06/04/07)
     
  45. EASL: Lipid steatosis, metabolic variables and body composition in the setting of HIV/HCV coinfection; findings from a large randomised trial (APRICOT) - (04/26/07)
     
  46. Blacks 51% of New HIV/AIDS Cases, Racial/Ethnic Disparities in Diagnoses of HIV/AIDS --- 33 States, 2001--2005 - (03/09/07)
     
  47. Belly fat may drive inflammatory processes associated with disease: diabetes, cancer, heart disease, hypertension - (03/09/07)
     
  48. Belly fat may drive inflammatory processes associated with disease: diabetes, cancer, heart disease, hypertension - (03/09/07)
     
  49. CROI: Osteopenia in HIV: risk factors for screeing (03/02/07)
     
  50. Growth Hormone-Releasing Hormone in HIV-Infected Men With Lipodystrophy - (02/09/07)
     
  51. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation - (02/09/07)
     
  52. 24% False HCV-Negative: among HCV-Antibody Negative, 24% Are HCV RNA+ If IDU & CD4 <200 - (01/17/07)
     
  53. Relation of d4T Discontinuation to Anthropometric Changes Among HIV-Infected Women in WIHS - (01/05/07)
     
  54. HIV Causes Heart Disease - (12/18/06)
     
  55. Increased carotid intima-media thickness in HIV patients is associated with increased (CMV) cytomegalovirus-specific T-cell responses; chronic viral Infections appear associated with Increased risk for heart disease - (12/15/06)
     
  56. Influence of pravastatin on carotid artery structure and function in dyslipidemic HIV-infected patients receiving ART - (12/15/06)
     
  57. Rosiglitazone Improved Fat Loss & Insulin in HIV+ with Insulin Resistance and Fat Redistribution - (12/12/06)
     
  58. Novartis starts major study of Galvus versus glitazones - (12/11/06)
     
  59. HIV-Infected from Human Immunodeficiency Virus-Infected - (12/11/06)
     
  60. Does rHGH Help or Harm Body Composition? - (12/11/06)
     
  61. rences in components of the metabolic syndrome betwe - (12/11/06)
     
  62. Pravastain + Exetimibe for LDL - (12/11/06)
     
  63. Longitudinal Anthropometric Changes in HIV-Infected and HIV-Uninfected Men - (12/11/06)
     
  64. Techniques for measuring regional body fat: computed tomography may be suitable for evaluation of facial lipoatrophy - (12/11/06)
     
  65. Incidence of Metabolic Syndrome in a Cohort of HIV-Infected Adults and Prevalence Relative to the US Population (National Health and Nutrition Examination Survey) - (12/11/06)
     
  66. Improved Triglycerides and Insulin Sensitivity with 3 Months of Acipimox in HIV+ Patients with Hypertriglyceridemia - (12/11/06)
     
  67. How Safe Are Facial Injectables? - (12/11/06)
     
  68. Primary Prevention of Cardiovascular Diseases With Statin Therapy - (12/11/06)
     
  69. Does HIV Cause Cardiovascular Disease? - (12/11/06)
     
  70. Rosiglitazone Increased Subcutaneous Fat - (12/11/06)
     
  71. New Weight Loss/Diabetes/Lipids Drug - (12/11/06)
     
  72. 8th Int Congress on Drug Therapy What's Better for High Lipids: Antilipid Drugs or NNRTI Switch? (11/16/06)
     
  73. 8th Int Congress on Drug Therapy The Metabolic Syndrome at Baseline in the D:A:D study 20% (11/15/06)
     
  74. 8th Intl Wrkshp Adverse Drug & Lipo: Comparison of the Effects on Body Composition of Rosiglitazone, Pravastatin, and Growth Hormone Alone and in Combination in the HIV-associated Lipoatrophy Treatment (HALT) Study - (10/17/06)
     
  75. 8th Intl Wrkshp Adverse Drug & Lipo: Mitochondrial function, morphology, and metabolic parameters improve after switching from a stavudine- to a tenofovir-containing regimen: SNAP (Switch Nucleoside Analogues Protocol) - (10/17/06)
     
  76. 8th Intl Wrkshp Adverse Drug & Lipo: Anti-inflammatory effects on body composition and metabolic alterations in HIV lipodystrophy: a pilot study - (10/17/06)
     
  77. Switch from Stavudine (d4T) to Tenofovir DF (TDF) in Combination with Lamivudine (3TC) and Efavirenz (EFV) Resulted in Continued Virologic Suppression and Improvement in Lipoatrophy Through 2 Years in HIV-Infected Patients - (09/29/06)
     
  78. 8th Intl Wrkshp Adverse Drug & Lipo: Pioglitazone Improves Limb Fat Loss - (09/26/06)
     
  79. 8th Intl Wrkshp Adverse Drug & Lipo: Systemic Errors in Estimating Renal Function by Cockroft-Gault or MDRD Equations - (09/26/06)
     
  80. 8th Intl Wrkshp Adverse Drug & Lipo: Improvement in Insulin Sensitivity and Dyslipidemia in Protease Inhibitor-Treated Patients After Switch to Atazanavir/Ritonavir (ATV/RTV): A Prospective Study Using Hyperinsulinemic, Euglycemic Clamp Testing - (09/26/06)
     
  81. 8th Intl Wrkshp Adverse Drug & Lipo: Risk of Hepatotoxicity in Virologically Suppressed HIV+ Patients switching to Nevirapine According to Gender & CD4 Count - (09/26/06)
     
  82. 8th Intl Wrkshp Adverse Drug & Lipo: Limb Fat Loss: nelfinavir, efavirenz, nukes - (09/26/06)
     
  83. New CVD, Blood pressure Drugs - (09/18/06)
     
  84. Diet & Exercise Counseling Program Improved Cardiovascular Risk Indices and Lipodystrophy - (09/18/06)
     
  85. Glucose lowering and diabetes prevention: are they the same? COMMENTARY - (09/18/06)
     
  86. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial - (09/18/06)
     
  87. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial - (09/18/06)
     
  88. The PROactive study: some answers, many questions - (09/18/06)
     
  89. Green Tea (5 cups) Daily Reduced Mortality & Cardiovascular Mortality - (09/15/06)
     
  90. Autoimmune Hepatitis Triggered by Statins - (09/15/06)
     
  91. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically - (09/08/06)
     
  92. Hypertension-Related Mortality Among Hispanic Subpopulations --- United States, 1995--2002 - (09/12/06)
     
  93. IAC: Older Age Associated with Reduced HAART Tolerabilty - (08/24/06)
     
  94. IAC: Switch from Kaletra to Reyataz (SWAN Study 48 weeks): lipids, viral suppression - (08/21/06)
     
  95. IAC: HIV+ Women in WIHS: 33% have Metabolic Syndrome - (08/17/06)
     
  96. IAC: Multiple Factors Predict Metabolic Syndrome in Women With HIV - (08/17/06)
     
  97. Diagnosis/Mgt of Body Changes & Lipid Abnormalities, Hyperlactatemia - (08/11/06)
     
  98. Antiretrovirals Induce Direct Endothelial Dysfunction In Vivo - (08/08/06)
     
  99. CD4 percentage is an independent predictor of survival in patients starting HAART with absolute CD4 cell counts between 200 and 350 cells/μL - (08/08/06)
     
  100. Endothelial Function in Patients with HIV Infection - (08/04/06)
     
  101. Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients - (08/04/06)
     
  102. Hypertension in HIV patients - (08/04/06)
     
  103. Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy - (08/04/06)
     
  104. Gout/hyperuricemia Increases Risk for Heart Disease - (08/04/06)
     
  105. BMI, Waist Size, and Fitness & Central Adiposity Associated with NAFLD (nonalcoholic fatty liver disease) - (07/30/06)
     
  106. GlaxoSmithKline announces FDA approval and the launch of Avandamet (rosiglitazone maleate and metformin HCl) as inital therapy in the treatment of type 2 diabetes - (07/30/06)
     
  107. Fat Distribution in Women With HIV Infection (FRAM) - (07/27/06)
     
  108. Uridine supplementation enhances hepatic mitochondrial function in thymidine-analogue treated HIV-infected patients - (07/20/06)
     
  109. Endothelial function in HIV-infected patients with low or mild cardiovascular risk - (07/07/06)
     
  110. Coadministration of Esomeprazole With Fosamprenavir Has No Impact on Steady-State Plasma Amprenavir Pharmacokinetics - (07/06/06)
     
  111. New Study Showed Vytorin Significantly More Effective than Crestor at Lower LDL - (06/22/06)
     
  112. Biggest Reduction in Bad Cholesterol Ever Achieved in a Clinical Trial after Trial with a combination of two lipid lowering agents - (06/20/06)
     
  113. Diabetes, Heart Disease, Prediabetes, Blood Pressure, Hypertension, Metabolic Syndrome, Cholesterol, Triglycerides & PREVENTION - (04/24/06)
     
  114. Heart Disease & Dietary Recommendations - (04/24/06)
     
  115. Genomic Mechanisms of Metabolic Complications & Management, 13th CROI 2006 - (04/19/06)
     
  116. Statins in HIV-associated lipodystrophy and metabolic syndrome: is there a missing link? - (04/11/06)
     
  117. Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy - (04/10/06)
     
  118. Mitochondrial disease: Powerhouse of disease-insulin resistance/diabetes - (04/10/06)
     
  119. Sculptra for Facial Lipoatrophy: New face sculpting changes lives for HIV patients - (04/10/06)
     
  120. Growth hormone secretion among HIV+ patients: effects of gender, race and fat distribution - (04/10/06)
     
  121. HAART & Elevated Blood Pressure - (04/10/06)
     
  122. Pravastatin Improves Fat Loss/Lipoatrophy - (04/10/06)
     
  123. SCULPTRA (Newfill) for HIV FACIAL LIPOATROPHY APPROVED BY FDA - (04/03/06)
     
  124. Sculptra, a procedure for facial lipoatrophy, is it for you? - (04/03/06)
     
  125. Ultrasound Technology Reduces Belly Fat - (03/22/06)
     
  126. HAART Associated with Subclinical Carotid Atherosclerosis, study finds - (03/22/06)
     
  127. CROI: The Take Home from CROI on Body Shape - Written for NATAP By David Alain Wohl, MD - The University of North Carolina AIDS Clinical Research and Treatment Unit (02/17/06)
     
  128. CROI: TESTOSTERONE EFFECT ON FAT MASS & DISTRIBUTION (02/13/06)
     
  129. CROI: Effect of pioglitazone on HIV-1 lipoatrophy : a randomised, double-bind, placebo-controlled trial (ANRS 113) (02/13/06)
     
  130. CROI: Metformin + Rosiglitazone for Lipodystrophy -Combination Study (02/13/06)
     
  131. CROI: Metformin for Lipodystrophy (02/13/06)
     
  132. CROI: Tenofovir+FTC Prevented HIV-Infection in Monkeys (02/13/06)
     
  133. Rimonabant Studied for Heart Disease & Alcohol Consumption Blocking - (02/08/06)
     
  134. Inhaled Insulin Gets FDA OK - (01/30/06)
     
  135. FDA Approves First Ever Inhaled Insulin Combination Product for Treatment of Diabetes - (01/30/06)
     
  136. Fatty Liver (Steatosis) May Cause Fibrosis & Liver Cancer - (01/30/06)
     
  137. Effects of Omega-3 Fatty Acids on Cancer Risk - (01/25/06)
     
  138. Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat? - (01/25/06)
     
  139. NYC Starts Diabetes Registry Mandatory Monitoring diabetes treatment in New York City - (01/25/06)
     
  140. Race, ethnicity & HIV drug impact - (01/24/06)
     
  141. Statins and colorectal cancer risk: A new panacea? - (01/24/06)
     
  142. Rosiglitazone/metformin Warns of Eye Complication that Appears to Occur Rarely - (01/19/06)
     
  143. Review article: drug therapy for non-alcoholic fatty liver disease - (01/12/06)
     
  144. Diabetes and Its Awful Toll Quietly Emerge as a Crisis: higher death rates than AIDS in NYC - (01/09/06)
     
  145. Diabetes, part 2 Living at an Epicenter of Diabetes, Defiance and Despair Bad Blood - (01/10/06)
     
  146. Pioglitazone May Reduce Signs of Metabolic Syndrome & Cardiovascular Risk in Nondiabetics as well as in Diabetics - (01/09/06)
     
  147. ICAAC: New CCR5 Inhibitor Zinc Finger Proteins (12/20/05)
     
  148. ICAAC: Towards Gene Knock Out Therapy for AIDS/HIV: Targeted Disruption of CCR5 Using Engineered Zinc Finger Protein Nucleases (ZFNs) (12/20/05)
     
  149. ICAAC: 13% Insulin Resistance in ART-Naive; Nevirapine is Only drug NOT associated with insulin resistance development (12/20/05)
     
  150. Insulin Resistance Raises Risk for Pancreatic Cancer, Study Finds - (12/14/05)
     
  151. 7th Int Wrkshp Drug & Lipo: Report from the 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV Carl Grunfeld, MD, PhD (12/13/05)
     
  152. EACS: Lipoatrophy Improved: RAVE Study (12/01/05)
     
  153. 7th Int Wrkshp Drug & Lipo: Hepatic steatosis: the common denominator for insulin resistance in obese and lipoatrophic subjects (12/09/05)
     
  154. Rosiglitazone lowers insulin resistance in nondiabetics - (12/09/05)
     
  155. Rosiglitazone improves exercise function in type 2 diabetes - (12/09/05)
     
  156. 7th Int Wrkshp Drug & Lipo: Mixed Results With Creatine During Exercise in People With HIV (11/17/05)
     
  157. 7th Int Wrkshp Drug & Lipo: Pravastatin for 12 Weeks Boosts Limb Fat in HIV+ Men (11/17/05)
     
  158. 7th Int Wrkshp Drug & Lipo: Dangerously High Lactates in Black Women Starting d4T (11/17/05)
     
  159. 7th Int Wrkshp Drug & Lipo: Can a "Polypill" Cut Heart Disease Risk in People With HIV? (11/17/05)
     
  160. 7th Int Wrkshp Drug & Lipo: Fatty Liver Found in Half of Study Group With HIV (11/17/05)
     
  161. 7th Int Wrkshp Drug & Lipo: Improving Lipoatrophy: Uridine and Pravastatin studies raise hope of new interventions to combat fat loss Graeme Moyle, MD, Chelsea & Westminster Hospital, London, UK (11/17/05)
     
  162. 7th Int Wrkshp Drug & Lipo: More Evidence Against Link Between Fat Loss and Gain With HIV Dr Graeme Moyle Chelsea and Westminster Hospital, London (11/17/05)
     
  163. AASLD: Diabetes Death & Complications May triple in Next 20 years (11/11/05)
     
  164. Belly Fat Accumulation in Children - (11/11/05)
     
  165. Metabolic syndrome cardiovascular disease risk and more - (11/04/05)
     
  166. Concluding remarks: metabolic syndrome, liver and HCV - (11/04/05)
     
  167. Perspectives on HIV/HCV co-infection, illicit drug use and mental illness: barriers to care - (11/01/05)
     
  168. The neuropsychological and neurological impact of HCV infection in HIV+ - (11/01/05)
     
  169. 17-40% of HCV-Infected Report Impaired Psych Function in HIV+ - (11/01/05)
     
  170. Predictors of Body Changes - (10/28/05)
     
  171. Provision or Distribution of Growth Hormone for "Antiaging" - (10/27/05)
     
  172. Efavirenz & AZT/3TC Did Not Cause Limb Fat Loss in ACTG 364 - (10/19/05)
     
  173. Nukes, Lactate, and Insulin Resistance - (10/13/05)
     
  174. A Randomized Trial of the Efficacy and Safety of Fenofibrate versus Pravastatin in HIV-Infected Subjects with Lipid Abnormalities: AIDS Clinical Trials Group Study 5087 - (10/13/05)
     
  175. Pioglitazone Reducd Risk for Heart Disease for Diabetics - (10/07/05)
     
  176. Undetectable HIV May Slow Fibrosis in HCV/HIV Coinfected Patients - (10/04/05)
     
  177. Fat Distribution in Men With HIV Infection - (10/03/05)
     
  178. Protease Inhibitors Adversely Affect Coronary Artery Function - (09/29/05)
     
  179. Insulin Resistance in HIV-Infected Men and Women in the Nutrition for Healthy Living Cohort - (09/27/05)
     
  180. HAART & Heart Disease: Antiretroviral therapy in HIV-positive men is associated with increased apolipoprotein CIII in triglyceride-rich lipoproteins - (09/15/05)
     
  181. Laser scanning as a tool for assessment of HIV-related facial lipoatrophy: evaluation of accuracy and reproducibility - (09/15/05)
     
  182. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C - (09/13/05)
     
  183. Adiponectin, Rosiglitazone, & Sugar Control; Adiponectin Found to be Protective in Fatty Liver Disease - (09/06/05)
     
  184. Comparison of Rosiglitazone and Metformin for Treating HIV Lipodystrophy: results suggest improvements in lipoatrophy associated with rosiglitazone. - (09/06/05)
     
  185. An Editorial Update: Annus horribilis for Vitamin E - (09/06/05)
     
  186. Study finds ddI but not d4T associated with risk for symptomatic mitochondrial toxicity in RIBAVIC during IFN/RBV therapy - (09/02/05)
     
  187. Effect of Antioxidants on Glucose Metabolism and Plasma Lipids in HIV-Infected Subjects With Lipoatrophy - (09/02/05)
     
  188. MITOCHONDRIAL DYSFUNCTION: TOXICITY & PATIENT MANAGEMENT - (09/02/05)
     
  189. TH9507, New Growth Hormone - (08/03/05)
     
  190. Current perspectives on HIV-associated lipodystrophy syndrome - (07/22/05)
     
  191. Metabolics, Fatty Liver, Heart Disease Circulatory dysfunction in NAFLD - Which is first, which is last, and what do we do in between? EDITORIAL - (07/21/05)
     
  192. Lipodystrophy: defined, risk factors, switch studies - (07/20/05)
     
  193. Fatty Liver Predicted Heart Disease - (07/20/05)
     
  194. Lipoatrophic men 44 months after the diagnosis of lipoatrophy are less lipoatrophic but more hypertensive - (07/13/05)
     
  195. Pioglitazone shows anti-inflammatory, anti-atherogenic effects - (07/13/05)
     
  196. Impact of rosiglitazone treatment on the bioavailability of antiretroviral compounds in HIV-positive patients - (07/13/05)
     
  197. Heart Disease: pioglitazone & fish - (06/24/05)
     
  198. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia - (06/20/05)
     
  199. New Oral Diabetes Drug Compared to Pioglitazone - (06/17/05)
     
  200. Diabetic Retinopathy Occurs in Pre-Diabetes - (06/14/05)
     
  201. Prevalence of, Evolution of, and Risk Factors for Fat Atrophy and Fat Deposition in a Cohort of HIV-Infected Men and Women - (06/7/05)
     
  202. NASH: a mitochondrial disease - (06/7/05)
     
  203. Diabetes risk high in men on HAART - (06/1/05)
     
  204. Pioglitazone: heart disease, lipids, diabetes - (05/31/05)
     
  205. Metabolic benefits, 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine, NEFA Study   - (05/24/05)
     
  206. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure - (05/24/05)
     
  207. Switching to Atazanavir Improves Metabolic Disorders in Antiretroviral-Experienced Patients With Severe Hyperlipidemia - (05/23/05)
     
  208. Body Changes in Women Associated with Heart Disease Risk: "Increased Cardiovascular Disease Risk Indices in HIV-Infected Women" - (05/04/05)
     
  209. Voluntary weight reduction tied to bone loss in older men - (04/22/05)
     
  210. Type 2 diabetes: principles of pathogenesis and therapy - (04/11/05)
     
  211. Cardiovascular disease in HIV-positive patients - (04/11/05)
     
  212. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy - (04/04/05)
     
  213. Treatment of Facial Lipoatrophy With Intradermal Injections of Polylactic Acid in HIV-Infected Patients - (03/21/05)
     
  214. Company Announces Sculptra Physician Locator - (03/15/05)
     
  215. CROI: Switch to Tenofovir Improved Lipids, Fat Loss - (03/15/04)
     
  216. Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy - (03/07/05)
     
  217. CROI: Improved Lipids After Switch to Reyataz - (03/04/04)
     
  218. CROI: Switch to ATV/r Improves Lipids - (03/04/04)
     
  219. Switch for Lipoatrophy to Abacavir or LPV/r+NVP - (03/02/05)
     
  220. CROI: Switching to Tenofovir or Lower d4T Dose Improves Lipids/Limb & Total Fat - (03/02/05)
     
  221. Reversal of HIV-1-associated osteoporosis with once-weekly alendronate - (03/02/05)
     
  222. CROI: RAVE Study: switch to tenofovir or abacavir from AZT or d4T - (03/01/05)
     
  223. Pioglitazone Improved Metabolic Syndrome - (02/16/05)
     
  224. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma (liver cancer) - (02/09/05)
     
  225. Body Habitus in a Cohort of HIV-Seropositive and HIV-Seronegative Injection Drug Users - (02/02/05)
     
  226. Increasing HDL May Reduce Heart Disease Risk - (02/01/05)
     
  227. Managing Cardiovascular Risk in Patients With HIV Infection - (01/28/05)
     
  228. Buffalo Hump May be Associated with High Insulin - (01/27/05)
     
  229. Diabetes, BMI, Belly Fat & Heart Disease - (01/19/05)
     
  230. Lopinavir/Ritonavir Plus Nevirapine as a Nucleoside-Sparing Approach in Antiretroviral-Experienced Patients (NEKA Study) - (01/18/05)
     
  231. Diabetes, high glucose levels linked to cancer in Korean study - (01/12/05)
     
  232. Rosiglitazone & Pioglitazone Treatment for Lipodystrophy, diabetes, effects on lipids - (01/10/05)
     
  233. PPAR{gamma}-mediated insulin sensitization: the importance of fat versus muscle - (01/10/05)
     
  234. Diabetes, Insulin Resistance, and Dementia Among HIV-1-Infected Patients - (01/10/05)
     
  235. Statins for Atherosclerosis — As Good as It Gets?, Editorial - (01/06/05)
     
  236. Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease - (01/06/05)
     
  237. C-Reactive Protein Levels and Outcomes after Statin Therapy - (01/06/05)
     
  238. Cardiovascular Risk and Body-Fat Abnormalities in HIV-Infected Adults - (01/06/05)
     
  239. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine - (01/04/05)
     
  240. Diabetes Deaths Increasing in NYC - (12/23/04)
     
  241. Fat Distribution in HIV-Infected Women in the United States: DEXA Substudy in the Women's Interagency HIV Study - (12/21/04)
     
  242. Loss of Subcutaneous Adipose Tissue in HIV-Associated Lipodystrophy Is Not Due to Accelerated Apoptosis - (12/21/04)
     
  243. Prevalence of hepatic steatosis (fatty liver) in an urban population in the United States: Impact of ethnicity - (12/13/04)
     
  244. Single-Slice Computed Tomography and Anthropometric Skinfold Analysis for Evaluation of Facial Lipoatrophy in HIV-Infected Patients - (12/03/04)
     
  245. Case-Control Study of Diabetes Mellitus in HIV-Infected Patients - (12/01/04)
     
  246. Mitochondrial Abnormalities in HIV-Infected Lipoatrophic Patients Treated With Antiretroviral Agents - (12/01/04)
     
  247. ICAAC: Side Effect Update: Hypersensitivity, Heart, Bones by Mark Mascolini - (11/15/04)
     
  248. IWADRL: Effects of Reyataz & Reyataz+ RTV on Lipids In Vitro by Graeme Moyle MD - (11/12/04)
     
  249. IWADRL: Lipids--the Liver & Heart Disease in HIV by Jacqueline Capeau - (11/12/04)
     
  250. AASLD: Body Changes, Diabetes, Fatty Liver & HIV & HCV - (11/05/04)
     
  251. IWADRL: Lipodystrophy Meeting Report: lipoatrophy; facial fillers by Graeme Moyle MD - (11/05/04)
     
  252. New Osteoporosis Drug Dosed by IV Every 2/3 Mos - (10/19/04)
     
  253. mtDNA Depletion & Coenzyme Q10 - (10/19/04)
     
  254. Adipose tissue expression of IL-18 and HIV-associated lipodystrophy - (09/28/04)
     
  255. Exercise test predicts heart disease in "healthy" men - (09/28/04)
     
  256. Switch to Nevirapine Improves Lipids - (09/22/04)
     
  257. Will the dietary intake of fish prevent atherosclerosis in diabetic women? - (09/10/04)
     
  258. Cardio- and cerebrovascular events in HIV-infected persons - (09/08/04)
     
  259. The Effects of Low-Dose Growth Hormone in HIV-Infected Men with Fat Accumulation: A Pilot Study - (09/07/04)
     
  260. Mitochondrial Effects of HIV In ART-Naive - (09/07/04)
     
  261. Effect of Nucleoside Reverse Transcriptase Inhibitors on Mitochondrial DNA Synthesis in Rats and Humans - (09/02/04)
     
  262. Tolerability and Safety of HIV Protease Inhibitors in Adults: heart, bones, lipids, body changes, diabetes - (08/27/04)
     
  263. Mitochondrial DNA Changes in PBMCs and Lipoatrophy & Nukes - (08/25/04)
     
  264. Metabolic complications of HIV therapy in children: lipodystrophy, dyslipidemias, insulin resistance, bones disease, avascular necrosis, mitochondrial toxicity - (08/20/04)
     
  265. Development of multiple lipomas during treatment with rosiglitazone in a patient with HIV-associated lipoatrophy - (08/19/04)
     
  266. XV International AIDS Conference in Bangkok: RE-EXAMINING WHEN TO BEGIN HIV THERAPY & D4T USE & LIPOATROPHY - (08/17/04)
     
  267. Niacin in HIV-Infected Individuals with Hyperlipidemia Receiving Potent Antiretroviral Therapy - (08/17/04)
     
  268. HCV Prevents Hypertriglyceridemia - (08/09/04)
     
  269. SCULPTRA for HIV FACIAL LIPOATROPHY APPROVED BY FDA - (08/04/04)
     
  270. XV International AIDS Conference in Bangkok: Risk of Metabolic Syndrome (MetSyn) Among Highly Treatment-Experienced HIV-Infected Patients -- 48 Week Results from BMS Study AI424-045 - (07/29/04)
     
  271. XV International AIDS Conference in Bangkok: Changes in Body Fat on Reyataz & Sustiva - (07/26/04)
     
  272. XV International AIDS Conference in Bangkok: Mitochondrial DNA depletion in HIV-infected patients is enhanced with chronic hepatitis C and treatment with pegylated interferon plus ribavirin - (07/22/04)
     
  273. XV International AIDS Conference in Bangkok: Lipids Changes in Reyataz Expanded Access Program - (07/20/04)
     
  274. XV International AIDS Conference in Bangkok: Effect on Glucose Metabolism by Adding Lo-Dose RTV to Reyataz: In Vitro study - (07/16/04)
     
  275. Switch from PI to Abacavir: affect on fat, glucose - (07/09/04)
     
  276. Clinical nutrition: Omega-3 fatty acids in cardiovascular care - (07/08/04)
     
  277. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection - (06/28/04)
     
  278. Sperm mitochondrial DNA deletions as a consequence of long term highly active antiretroviral therapy - (06/28/04)
     
  279. Polyunsaturated Ethyl Esters of n-3 Fatty Acids in HIV-Infected Patients With Moderate Hypertriglyceridemia: Comparison With Dietary and Lifestyle Changes, and Fibrate Therapy - (06/22/04)
     
  280. Body Changes in HIV+ Monkeys - (06/07/04)
     
  281. High Plasma Level of Interleukin-18 in HIV-Infected Subjects With Lipodystrophy - (05/12/04)
     
  282. Lipoatrophy & Switch to Abacavir: Mitox Study - (05/11/04)
     
  283. Factors Associated with Severe Impact of Lipodystrophy on the Quality of Life of Patients Infected with HIV-1 - (05/04/04)
     
  284. HCV/HIV Coinfection & Lipid Abnormalities - (05/04/04)
     
  285. Beneficial effects of oral uridine in mitochondrial toxicity - (05/03/04)
     
  286. Mitochondrial damage and DNA depletion in cord blood and umbilical cord from infants exposed in utero to Combivir - (05/03/04)
     
  287. CROI: Body Changes, Toxicity, Efficacy: d4T vs Abacavir, plus 3TC/EFV - (04/12/04)
     
  288. 384 HIV+ Men found to have Body Abnormalities Compared to 314 HIV- Men - (04/05/04)
     
  289. Report 2 on Sculptra (Newfill): FDA study review; advocacy issues - (03/29/04)
     
  290. CROI: Alendronate And Osteopenia and Osteoporosis - (03/17/04)
     
  291. CROI: Insulin Resistance/Diabetes and HIV and Hepatitis C; Aging/HIV & diabetes - (03/12/04)
     
  292. CROI: Effects of Fuzeon on Body Composition and Lipids Through 48 weeks in the TORO Trials - (03/02/04)
     
  293. CROI: PegIntron Plus Ribaivin in HCV/HIV Coinfection: French RIBAVIC Study - (02/19/04)
     
  294. CROI: ACTG 5071: Pegasys plus Ribavirin vs IFN/RBV in HCV/HIV Coinfection - (02/19/04)
     
  295. CROI: Body Shape at CROI: rosiglitazone, Newfill, Fuzeon, PI-switch study, d4T-XR, FTC, face ultrasound, Atlantic & NEFA studies - Written by David Alain Wohl, MD (02/19/04)
     
  296. CROI: The Effect of Atazanavir vs Lopinavir/ritonavir on Insulin-Stimulated Glucose Disposal Rate in Healthy Subjects - (02/17/04)
     
  297. CROI: No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial - (02/17/04)
     
  298. Antiretroviral nucleoside and nucleotide analogues and mitochondria - (02/05/04)
     
  299. Acute myocardial infarction in patients infected with HIV - (01/14/04)
     
  300. AIDS increases risk of stroke - (01/14/04)
     
  301. Pioglitazone Improves Liver, Body Fat, Glucose - (01/08/04)
     
  302. Reyataz vs Nelfinavir: phase II study - (01/06/04)
     
  303. Lipoatrophy Improvement Following switch to Abacavir or AZT from d4T - (01/05/04)
     
  304. Stampede of Diabetes as U.S. Races to Obesity - (12/29/03)
     
  305. Overweight & Fatty Liver Accelerates Activity and Progression of HCV - (12/29/03)
     
  306. HCV-Coinfection Is Associated with Diabetes and CD4 Decline - (12/29/03)
     
  307. Antiretrovirals and Cardiovascular Disease: Is HAART Bad for Your Heart? - (12/22/03)
     
  308. Alanine Aminotransferase Levels Predict Insulin Resistance in HIV Lipodystrophy - (12/08/03)
     
  309. Increased Risk for Fat Loss in HIV+ Women Observed in WIHS Study - (12/08/03)
     
  310. Ultrasound Assisted Liposuction Reduces Buffalo Hump - (11/30/03)
     
  311. AIDS Drugs Increase Risk of Heart Attack; But Study Indicates Benefit of Therapy Exceeds Threat - (11/30/03)
     
  312. Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis - (11/26/03)
     
  313. How bad is HAART for the HEART? - (11/24/03)
     
  314. Combination Antiretroviral Therapy and the Risk of Myocardial Infarction - (11/20/03)
     
  315. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men - (11/17/03)
     
  316. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA - (11/17/03)
     
  317. Living with HIV Therapy: Effects of HIV Infection and Treatment on Physical Appearance and Body Image - (11/17/03)
     
  318. EACS - Switching from PI to Trizivir or Nevirapine Due to Lipid Abnormalities - (11/17/03)
     
  319. Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes: A Randomized Controlled Trial - (11/10/03)
     
  320. Overcoming subjectivity in assessing facial lipoatrophy: is there a role for three-dimensional laser scans? - (10/24/03)
     
  321. Cardiac surgery in patients infected with the human immunodeficiency virus - (10/24/03)
     
  322. Lipodystrophy in human immunodeficiency virus patients impairs insulin action and induces defects in beta-cell function - (10/24/03)
     
  323. Brief Report: Gender Differences in Antiretroviral Drug-Related Adipose Tissue Alterations: Women Are at Higher Risk Than Men and Develop Particular Lipodystrophy Patterns - (10/15/03)
     
  324. Factors Associated With Mitochondrial Dysfunction in Circulating Peripheral Blood Lymphocytes From HIV-Infected People - (10/15/03)
     
  325. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-y ligand rosiglitazone - (9/30/03)
     
  326. Hyperlactatemia in HIV: Frequency, risk factors and features of hyperlactatemia in a large number of patients undergoing antiretroviral therapy - (9/30/03)
     
  327. Evaluation of Computed Tomography and Ultrasonography for Assessment of Facial Fat in HIV-Infected Patients - (9/29/03)
     
  328. Pioglitazone in Lipodystrophy - (9/10/03)
     
  329. Guidelines for Dyslipidemia (PDF) - (9/2/03)
     
  330. Changes in Metabolic Profile Among Antiretroviral-Naïve Patients Initiating Protease Inhibitor Versus Non-Protease Inhibitor Containing HAART Regimens - (8/27/03)
     
  331. Decreased Bone Mineral Density Due to Time with HIV, not ART - (8/25/03)
     
  332. Treatments for lipoatrophy. Are there improvements? Are they noticeable? - (8/25/03)
     
  333. Bone Effects of Tenofovir - (8/19/03)
     
  334. Switch From NNRTI Regimen to Trizivir: viral load & choleserol changes - (8/18/03)
     
  335. The Effect of HAART and HCV Infection on the Development of Hyperglycemia Among HIV-Infected Persons - (8/14/03)
     
  336. Brief Report: Effect of Antioxidants on Glucose Metabolism and Plasma Lipids in HIV-Infected Subjects With Lipoatrophy - (8/14/03)
     
  337. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort - (8/11/03)
     
  338. STIs and Effect on Lipids, HIV Drug Resistance, and Viral Load - (8/7/03)
     
  339. Lipoatrophy and Mitochondrial Toxicity Issues at the 5th Lipodystrophy Conference - Cecilia Shikuma, MD, University of Hawaii and the ACTG (8/4/03)
     
  340. Glucose metabolism/insulin resistance, lipids and cardiovascular: report from Paris, IAS & Lipodystrophy Conferences - Michael Dube, MD, University of Indiana and the ACTG (7/10/03)
     
  341. Recombinant Human Growth Hormone (r-hGH) Reported by Judith Aberg, MD , Washington University, St Louis, Missouri and the ACTG - (7/22/03)
     
  342. HIV Infection-A Risk Factor for Osteoporosis - (7/7/03)
     
  343. Bone Mass in HIV-Infected Patients: Focus on the Role of Therapy and Sex - (7/7/03)
     
  344. Hepatitus C Therapeutic Vaccine: study data released - (7/7/03)
     
  345. High Prevalence of Elevated Lipids Observed in Children on HAART - (6/25/03)
     
  346. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy - (6/25/03)
     
  347. Serostim (HGH) on Black Market for Body Builders - (6/11/03)
     
  348. Inclusion body myositis: another possible manifestation of antiretroviral-associated mitochondrial toxicity - (6/5/03)
     
  349. Switching to Abacavir or Trizivir for Lipodystrophy & Lipids - (5/28/03)
     
  350. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy - (4/17/03)
     
  351. Rapid development of central adiposity after postexposure prophylaxis with antiretroviral drugs: a proof of principle? - (4/15/03)
     
  352. Factors associated with the development of diabetes mellitus in HIV-infected patients on antiretroviral therapy: a case-control study - (4/15/03)
     
  353. Prediction of Coronary Heart Disease Risk in HIV-Infected Patients with Fat Redistribution - (4/4/03)
     
  354. Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy: in small pilot study - (4/2/03)
     
  355. Protease Inhibitor Use and the Incidence of Diabetes Mellitus in a Large Cohort of HIV-Infected Women - (4/2/03)
     
  356. Retro - Preliminary Study of Fosomax for Bone Mineral Loss in HIV (3/31/03)
     
  357. Emerging Reconstruction Procedures for HIV Facial Wastings By Nelson Vergel - (3/28/03)
     
  358. PPAR-gamma important in triglyceride and glucose regulation
    03/12/03
     
  359. Hepatitis C Virus in Patients With HIV Infection and Lipodystrophy - (3/12/03)
     
  360. Severe Hepatotoxicity During Combination Antiretroviral Treatment: Incidence, Liver Histology, and Outcome - (3/12/03)
     
  361. Impaired Insulin Sensitivity in HIV-infected Individuals is Associated with Higher Hepatic Lipid Content and Visceral Adiposity - (3/10/03)
     
  362. Retro - Evidence Suggesting Mitochondrial Toxicity in HIV/HCV Co-infected Patients Receiving Ribavirin and Didanosine - (3/10/03)
     
  363. Retro - Incidence of Lipoatrophy and Lipohypertrophy in the Women's Interagency HIV Study - (3/10/03)
     
  364. Retro - Fat and Bone: What D:A:D Says and Other Strangeness at CROI David Alain Wohl, MD - The University of North Carolina - (3/10/03)
     
  365. Rosiglitazone improves insulin sensitivity, lowers blood pressure in hypertensives
    01/24/03
     
  366. Excess prostate cancer risk associated with high bone mass
    01/24/03
     
  367. Serum Retinol Levels and the Risk of Fracture (1/23/03)
     
  368. Food Combo as Good as Cholesterol Drugs - By Daniel DeNoon Source: WebMD Medical News - (1/7/03)
     
  369. Osteonecrosis in HIV disease: epidemiology, etiologies, and clinical management - (12/16/02)
     
  370. Protease inhibitors and cardiovascular outcomes in patients with HIV-1 - (12/05/02)
     
  371. PDF FORMAT - Management of Metabolic Complications Associated With Antiretroviral Therapy for HIV-1 Infection: Recommendations of an International AIDS Society-USA Panel - (12/02/02)
     
  372. F.D.A. Approves New Osteoporosis Therapy, a Bone-Growing Drug By THE ASSOCIATED PRESS - (12/02/02)
     
  373. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy - (12/02/02)
     
  374. Improved Insulin Sensitivity and Body Fat Distribution in HIV-Infected Patients Treated With Rosiglitazone: A Pilot Study - (11/19/02)
     
  375. 4th Lipodystrophy Workshop: metabolic abnormalities, HCV/HIV coinfection, fat loss, HCV/HIV coinfection - Michael Dube, MD, Indiana University School of Medicine, ACTG researcher - (10/30/02)
     
  376. ICAAC - Perspectives on hormonal, mitochondrial and metabolic changes - Reported by Mike Youle, MD, Royal Free Hospital, London - (10/15/02)
     
  377. Lipid Analysis in Efavirenz & Nelfinavir Regimens - (10/8/02)
     
  378. Switch Study in Children to Efavirenz from Protease Inhibitor - (10/8/02)
     
  379. Effect of d4T and AZT on Leg Fat Loss - (10/7/02)
     
  380. Lipodystrophy, lactic acidosis/acidemia and mitochondrial toxicity issues - Written by Cecilia Shikuma, MD, University of Hawaii and ACTG lipodystrophy researcher - (10/7/02)
     
  381. Effect of protease inhibitors on bone - Special report by Donald P. Kotler, MD, St Luke's-Roosevelt Medical Center, New York City - (9/26/02)
     
  382. Barcelona Italian Heart Disease Study Withdrawn - (10/7/02)
     
  383. ICCAC - Integrase Inhibitors Advancing: S-1360 & metabolic abormalities - (10/1/02)
     
  384. HCV Viral Load Increases on HAART But CD4 Increase from HAART is Not Blunted: implications for when to begin HIV & HCV therapy - (9/26/02)
     
  385. HIV/Hepatitis & Insulin/Diabetes - (9/26/02)
     
  386. Body Composition Changes Observed in ACTG 384 - (9/26/02)
     
  387. Treating Diarrhea in HIV - (9/25/02)
     
  388. 36-week Safety and Tolerability Study of Extended-Release Niacin (ERN) for the Treatment of Elevated Triglycerides in HIV - (9/25/02)
     
  389. Nukes, Fat Loss, Mitochondrial Toxicity, Lactate - discussed below - (9/25/02)
     
  390. Switch Study From Nelfinavir to Atazanavir - (9/24/02)
     
  391. Atazanavir: preliminary week 24 study results show no increase in glucose, cholesterol and triglycerides - (9/24/02)
     
  392. LIPODYSTROPHY WORKSHOP day 1 - (9/23/02)
     
  393. OSTEOPENIA IN HIV: tests and markers to evaluate bone loss - (9/23/02)
     
  394. Cardiovascular Risk Associated With HIV Therapy: review by Judith Currier, MD - (9/13/02)
     
  395. Bananas May Beat Stroke Low-Potassium Diet Raises Stroke Risk - (9/13/02)
     
  396. Women With Impaired Glucose Tolerance During Pregnancy Have Significantly Poor Pregnancy Outcomes - (8/27/02)
     
  397. Depression & Anxiety Can Occur in Diabetics and Their Partners, Particularly Women - (8/27/02)
     
  398. Diabetes, Insulin Resistance, Belly Fat Gain in HIV - (8/19/02)
     
  399. ACTG Metabolic Complications Guide:PDF Format:
    lipodystrophy PDF
    bone disorders PDF
    fat accumulation PDF
    lipoatrophy PDF
    hyperlactatemia PDF
    diabetes and insulin resistance PDF - (8/14/02)
     
  400. FRAM Study and Lipodystrophy: lipodystrophy study presented at Barcelona and an interview with the study author Carl Grunfeld - (8/9/02)
     
  401. Barcelona - Metabolic Complications of HIV and its Therapies: What Did We Learn in Barcelona? - (7/25/02)
     
  402. Barcelona - A Lipodystrophy Reformation? - (7/16/02)
     
  403. Barcelona - Lipoatrophy Didn't Improve: switch to PI-Sparing - (7/10/02)
     
  404. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy (HIV negative) - (05/31/02)
     
  405. Lipodystrophy Conference in Marbella, Spain Reported for NATAP by Mike Youle, MD, Royal Free Hospital, London, UK - (5/06/02)
     
  406. Tenofovir & Bones in Monkeys (05/2/02)
     
  407. Calcium plus protein equals strong bones: study
    04/30/02
     
  408. Skeletal muscle mitochondrial function and exercise capacity in HIV-infected patients with lipodystrophy and elevated p-lactate levels PDF
    (04/22/02)
     
  409. Rosiglitazone In The Treatment of HAART-Associated Lipodystrophy: a randomized, double-blinded, placebo controlled study Written by Jules Levin (03/28/02)
     
  410. HIV and Cardiovascular Disease: True True or Unrelated? The Debate Continues - Reported by Judith Aberg, MD, Medical Director, HIV Services, washington University School of Medicine, St. Louis, and ACTG researcher - (03/11/02)
     
  411. Switching Antiretroviral Therapy for Lipoatrophy
    David Alain Wohl, MD - University of North Carolina AIDS Treatment and Research Center
    (03/3/02)
     
  412. Attacking Lipodystrophy
    David Alain Wohl, MD - University of North Carolina AIDS Treatment and Research Center
    (03/3/02)
     
  413. HIV Lipodystrophy & Metabolic Studies at Massachusetts General Hospital in Boston For Men
     
  414. HIV Lipodystrophy & Metabolic Studies at Massachusetts General Hospital in Boston For Women
     
  415. Summary Review of the Lipodystrophy Conference 2001
     
  416. Fat Loss, Fat Gain and Related Metabolic Abnormalities in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy (HAART); interview with Steven Grinspoon, MD, Mass General, noted researcher
     
  417. Abnormalities of Glucose Metabolism, Including Insulin Resistance
     
  418. Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome
     
  419. Risk for Increased Heart Disease in 45-Year Old Women with HIV and Lipodystrophy
     
  420. Lipodystrophy, Protease Inhibitors, and Insulin Resistance
     
  421. Amprenavir and Effects on Metabolics & Lipoatrophy
     
  422. Bulletted Highlights From Lipodystrophy and Adverse Drug Reactions in HIV Workshop
     
  423. Abacavir: Fat Redistribution, and Changes in Cholesterol & Triglycerides
     
  424. Mitochondrial Toxicity and Lipodystrophy
     
  425. Nevaripine: lipids and heart disease; hepatotoxicity and a role for therapeutic drug monitoring
     
  426. High prevalence of Thyroid Abnormalities in the era of HAART
     
  427. Report on Lactic Acidosis and other Mitochondrial Toxicity Issues
     
  428. Report on Possible Therapy for Lipodystrophy
     
  429. LIPID ABNORMALITIES AND CARDIOVASCULAR RISK
     
  430. The Evaluation and Management of Hyperlipidemia In HIV Infection
     
  431. Metformin in the Treatment of HIV Lipodystrophy Syndrome: A Randomized Controlled Trial
     
  432. Review of Studies on Bone Problems at ICAAC and Lipodystrophy Workshop
     
  433. Switching Therapy Studies and Responses in Lipodystrophy
     
  434. Review of Studies on Bone Problems at ICAAC and Lipodystrophy Workshop
     
  435. Report 3 from Lipodystrophy Conference
     
  436. Indinavir+Ritonavir; New Merck 2nd Generation ProteaseInhibitor; Dr Don Kotler on Lipodystrophy
     
  437. Spring 2001 Report - Adverse Effects & Complications
     
  438. Lipodystrophy in patients with HIV-1 infection: effect of stopping protease inhibitors on TNF-re
     
  439. Gender Differences in Morphologic Alterations (Body Changes or Lipodystrophy)
     
  440. Lipodystrophy in patients with HIV-1 infection: effect of stopping protease inhibitors on TNF-re
     
  441. MACS Database on Lipodystrophy: prevalence of body changes & lab abnormalities
     
  442. Lipodystrophy Workshop
     
  443. Does Stopping PI Reverse Lipodystrophy?
     
  444. New Resistance "Cut-Offs" May Be Needed: Baseline Genotype and Phenotype Do Not Predic
     
  445. Report 2 from Lipodystrophy Conference - NRTIs and Fat Redistribution
     
  446. Selected Reports from The Lipodystrophy Workshop in Toronto
     
  447. Fat City: Understanding HIV Lipodystrophy
     
  448. Lipodystrophy: Mitochondrial Toxicity and Lactate Levels
     
  449. Lipodystrophy May Be Related to Cortisol:DHEA Ratio and Serum Alpha-Interferon
     
  450. Nucleosides (NRTIs) and Reduced Bone Mineral Density (Osteopenia)
     
  451. Switching PI Therapy to Amprenavir & The Affect on Lipodystrophy & Lipids
     
  452. Switching to Nevirapine from Protease Inhibitor for Lipodystrophy: preliminary 48-week follow-up
     
  453. HGH in Treating Fat Redistribution or Lipodystrophy
     
  454. 4th Intl Conference on Nutrition and HIV Infection
     
  455. Perspectives on Lipodystrophy: What have we learned about the cause?
     
  456. Selected Brief Highlights from the Lipodystrophy Conference
     
  457. Fat Redistribution, Lipodystrophy and Related Issues
     
  458. Lipodystrophy Following HAART in Acute HIV
     
  459. Lipodystrophy or Fat redistribution
     
  460. Therapeutic Intervention for Lipodystrophy.
     
  461. Lipodystrophy & Women: how long after starting therapy does it take for lipodystrophy to dev
     
  462. Highlights on Lipodystrophy (Fat Redistribution) and Adverse Effects of Anti-HIV Drugs
     
  463. NATAP - Hepatitis; Adverse Events(Lipodystrophy, hypersenstivity, hepatotoxicity, bone problems
     
  464. Pediatrics, Antiretroviral Treatment, Lipodystrophy, ABT-378 in Naive & Experienced Children
     
  465. Osteopenia in HIV Infection
     
  466. Association of Severe Insulin Resistance With Both Loss of Limb Fat and Elevated Serum Tumor Nec
     
  467. NATAP at the Durban World AIDS Conference 2000 Durban
     
  468. Mitochondrial Toxicity (Part 2)
     
  469. NATAP is at the 7th Conference on Retroviruses and Opportunistic Infections
     
  470. Bone Mineral Density
     
  471. Fat Redistribution and Metabolic Disturbances - Rpt 1 - 7th Conference
     
  472. Preliminary Study on Changes in Lipids, Insulin and Body Changes During 12-Week STI
     
  473. Switching to Protease Inhibitor Sparing Studies
     
  474. Glasgow Wednesday Brief Update Report
     
  475. Bone Abnormalities at ICAAC: Osteoporosis, Osteonecrosis
     
  476. Does Switching Therapy Improve Body Changes & Lab Abnormalities?